Iptacopan hydrochloride
( DrugBank: Iptacopan / KEGG DRUG: Iptacopan, Iptacopan hydrochloride )
4 diseases
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
61 | Autoimmune hemolytic anemia | 1 |
66 | IgA nephropathy | 13 |
ID | Disease name (Link within this page) | Number of trials |
---|---|---|
109 | Atypical hemolytic uremic syndrome | 1 |
222 | Primary nephrotic syndrome | 2 |
61. Autoimmune hemolytic anemia
Clinical trials : 183 / Drugs : 119 - (DrugBank : 42) / Drug target genes : 31 - Drug target pathways : 156
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
66. IgA nephropathy
Clinical trials : 349 / Drugs : 251 - (DrugBank : 75) / Drug target genes : 43 - Drug target pathways : 152
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
109. Atypical hemolytic uremic syndrome
Clinical trials : 123 / Drugs : 29 - (DrugBank : 6) / Drug target genes : 2 - Drug target pathways : 11
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|
222. Primary nephrotic syndrome
Clinical trials : 382 / Drugs : 278 - (DrugBank : 98) / Drug target genes : 73 - Drug target pathways : 197
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|